133 related articles for article (PubMed ID: 9364254)
1. Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.
Lupoli G; Di Carlo C; Nuzzo V; Vitale G; Russo D; Palomba S; Nappi C
J Endocrinol Invest; 1997 Sep; 20(8):493-6. PubMed ID: 9364254
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of polycystic ovary syndrome.
Ehrmann DA; Rychlik D
Semin Reprod Med; 2003 Aug; 21(3):277-83. PubMed ID: 14593550
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Moghetti P; Castello R; Zamberlan N; Rossini M; Gatti D; Negri C; Tosi F; Muggeo M; Adami S
J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with GnRH analogs in polycystic ovarian disease. A collaborative multicenter study. The preliminary results].
Cipolla L; Zagni R; Ferrante B; Giannetta G; Soliani A
Minerva Ginecol; 1994 Mar; 46(3):85-9. PubMed ID: 8015704
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea.
Di Carlo C; Shoham Z; MacDougall J; Patel A; Hall ML; Jacobs HS
Fertil Steril; 1992 Feb; 57(2):314-9. PubMed ID: 1735481
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of gonadotropin-releasing hormone agonists in polycystic ovarian syndrome.
Markussis V; Goni MH; Tolis G
Ann N Y Acad Sci; 1993 May; 687():242-9. PubMed ID: 8323179
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism.
Falsetti L; Pasinetti E; Ceruti D
Acta Eur Fertil; 1994; 25(5):303-6. PubMed ID: 7660719
[TBL] [Abstract][Full Text] [Related]
9. [Revelation of a polymicrocystic ovary syndrome after one month's treatment by pulsatile GnRH in a patient presenting with functional hypothalamic amenorrhea].
Reyss AC; Merlen E; Demerle C; Dewailly D
Gynecol Obstet Fertil; 2003 Dec; 31(12):1039-42. PubMed ID: 14680786
[TBL] [Abstract][Full Text] [Related]
10. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
11. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
12. Hyperandrogenemia association with acne and hirsutism severity in Croatian women with polycystic ovary syndrome.
Pavičić Baldani D; Škrgatić L; Bukvić Mokos Z; Trgovčić I
Acta Dermatovenerol Croat; 2013; 21(2):105-12. PubMed ID: 24001418
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
[TBL] [Abstract][Full Text] [Related]
14. [Pituitary response to GnRH analogue testing in girls with a polycystic ovary syndrome].
Wikiera B; Wasikowa R
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):13-8. PubMed ID: 16704856
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
16. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
Lemay A; Faure N
J Clin Endocrinol Metab; 1994 Dec; 79(6):1716-22. PubMed ID: 7989480
[TBL] [Abstract][Full Text] [Related]
17. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
[TBL] [Abstract][Full Text] [Related]
18. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
19. [Polycystic ovary. The PCO syndrome].
Goldenstein S; Sillem M
Med Monatsschr Pharm; 2002 Jul; 25(7):233-5. PubMed ID: 12148236
[No Abstract] [Full Text] [Related]
20. Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review.
Mason H; Colao A; Blume-Peytavi U; Rice S; Qureshi A; Pellatt L; Orio F; Atkin SL
Clin Endocrinol (Oxf); 2008 Dec; 69(6):831-44. PubMed ID: 18616705
[No Abstract] [Full Text] [Related]
[Next] [New Search]
